Compare ERAS & CSR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ERAS | CSR |
|---|---|---|
| Founded | 2018 | 1970 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.1B |
| IPO Year | 2021 | N/A |
| Metric | ERAS | CSR |
|---|---|---|
| Price | $9.53 | $64.29 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 7 |
| Target Price | $5.33 | ★ $70.50 |
| AVG Volume (30 Days) | ★ 7.9M | 146.2K |
| Earning Date | 11-12-2025 | 02-17-2026 |
| Dividend Yield | N/A | ★ 4.76% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 1.82 |
| Revenue | N/A | ★ $273,450,000.00 |
| Revenue This Year | N/A | $6.83 |
| Revenue Next Year | N/A | $3.14 |
| P/E Ratio | ★ N/A | $35.46 |
| Revenue Growth | N/A | ★ 5.72 |
| 52 Week Low | $1.01 | $52.76 |
| 52 Week High | $9.87 | $69.15 |
| Indicator | ERAS | CSR |
|---|---|---|
| Relative Strength Index (RSI) | 88.98 | 42.61 |
| Support Level | $3.36 | $64.32 |
| Resistance Level | $6.49 | $67.74 |
| Average True Range (ATR) | 1.01 | 1.83 |
| MACD | 0.57 | -0.34 |
| Stochastic Oscillator | 92.85 | 15.99 |
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.
Centerspace is a real estate investment trust (REIT) that focuses on the ownership, management, acquisitions, redevelopment, and development of apartment communities. The company operates through a single reportable segment which includes the ownership, management, development, redevelopment, and acquisition of apartment communities and conduct their corporate operations from offices in Minot, North Dakota and Minneapolis, Minnesota.